secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K/A
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001193125-23-262976
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carmell Corp files Axolotl Biologix H1 2023 financials: rev $21.9M, NI $1.8M
----------------------------------------------------------------------------

- Axolotl H1 2023 revenue $21.9M (up 56% YoY from $14.0M) and net income $1.8M (up 57% from $1.2M).
- Single customer (Customer A) and single product (Dualgraft) represent 100% of revenue.
- Cash and equivalents $698k; accounts receivable $17.2M; inventory $2.6M.
- Related-party loans from Burns Ventures $5.6M noncurrent; inventory purchases from Pinnacle $2.5M in H1 2023.
- Operating cash flow negative $701k; cash decreased from $1.4M to $698k in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/0001193125-23-262976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/d568161d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-262976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer